Braveheart Bio's Hengrui-licensed cardiac drug scores second clinical win

May 11, 2026 09:42 AM EDT R&D Brave­heart Bio's Hen­grui-li­censed car­diac drug scores sec­ond clin­i­cal win Elizabeth Cairns Senior biopharma journalist Brave­heart Bio said Mon­day that the heart mus­cle ther­a­py it li­censed from Chi­na’s Jiang­su Hen­grui Phar­ma­ceu­ti­cals has suc­ceed­ed in a mid-stage tri­al for the same … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER